cbio-10q_20200930.htm
false Q3 0001124105 --12-31 P12M P8Y1M24D P8Y1M2D P6Y0M22D P5Y10M25D P5Y9M11D P5Y11M23D 0001124105 2020-01-01 2020-09-30 xbrli:shares 0001124105 2020-10-29 iso4217:USD 0001124105 2020-09-30 0001124105 2019-12-31 iso4217:USD xbrli:shares 0001124105 cbio:LicenseRevenueMember 2020-07-01 2020-09-30 0001124105 cbio:LicenseRevenueMember 2020-01-01 2020-09-30 0001124105 cbio:CollaborationRevenueMember 2020-07-01 2020-09-30 0001124105 cbio:CollaborationRevenueMember 2020-01-01 2020-09-30 0001124105 2020-07-01 2020-09-30 0001124105 cbio:CostOfLicenseMember 2020-07-01 2020-09-30 0001124105 cbio:CostOfLicenseMember 2020-01-01 2020-09-30 0001124105 cbio:CostOfCollaborationMember 2020-07-01 2020-09-30 0001124105 cbio:CostOfCollaborationMember 2020-01-01 2020-09-30 0001124105 2019-07-01 2019-09-30 0001124105 2019-01-01 2019-09-30 0001124105 us-gaap:CommonStockMember 2019-12-31 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001124105 us-gaap:RetainedEarningsMember 2019-12-31 0001124105 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001124105 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001124105 2020-01-01 2020-03-31 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001124105 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001124105 us-gaap:CommonStockMember 2020-03-31 0001124105 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001124105 us-gaap:RetainedEarningsMember 2020-03-31 0001124105 2020-03-31 0001124105 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001124105 2020-04-01 2020-06-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001124105 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001124105 us-gaap:CommonStockMember 2020-06-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001124105 us-gaap:RetainedEarningsMember 2020-06-30 0001124105 2020-06-30 0001124105 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001124105 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001124105 us-gaap:CommonStockMember 2020-09-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001124105 us-gaap:RetainedEarningsMember 2020-09-30 0001124105 us-gaap:CommonStockMember 2018-12-31 0001124105 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001124105 us-gaap:RetainedEarningsMember 2018-12-31 0001124105 2018-12-31 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001124105 2019-01-01 2019-03-31 0001124105 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001124105 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001124105 us-gaap:CommonStockMember 2019-03-31 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001124105 us-gaap:RetainedEarningsMember 2019-03-31 0001124105 2019-03-31 0001124105 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001124105 2019-04-01 2019-06-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001124105 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001124105 us-gaap:CommonStockMember 2019-06-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001124105 us-gaap:RetainedEarningsMember 2019-06-30 0001124105 2019-06-30 0001124105 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001124105 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001124105 us-gaap:CommonStockMember 2019-09-30 0001124105 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001124105 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001124105 us-gaap:RetainedEarningsMember 2019-09-30 0001124105 2019-09-30 cbio:Segment 0001124105 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-09-30 0001124105 us-gaap:MoneyMarketFundsMember 2020-09-30 0001124105 us-gaap:FairValueInputsLevel1Member us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001124105 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001124105 us-gaap:FairValueInputsLevel2Member cbio:ShortTermAndLongTermInvestmentsMember cbio:FederalAgencySecuritiesMember 2020-09-30 0001124105 cbio:ShortTermAndLongTermInvestmentsMember cbio:FederalAgencySecuritiesMember 2020-09-30 0001124105 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001124105 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001124105 cbio:LongTermInvestmentsMember cbio:FederalAgencySecuritiesMember 2020-09-30 0001124105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001124105 us-gaap:MoneyMarketFundsMember 2019-12-31 0001124105 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001124105 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001124105 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member cbio:FederalAgencySecuritiesMember 2019-12-31 0001124105 us-gaap:ShortTermInvestmentsMember cbio:FederalAgencySecuritiesMember 2019-12-31 0001124105 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001124105 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001124105 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2020-09-30 0001124105 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001124105 cbio:FederalAgencySecuritiesMember 2020-09-30 0001124105 us-gaap:CashAndCashEquivalentsMember 2020-09-30 0001124105 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001124105 cbio:LongTermInvestmentsMember 2020-09-30 0001124105 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2019-12-31 0001124105 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001124105 cbio:FederalAgencySecuritiesMember 2019-12-31 0001124105 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001124105 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001124105 2020-07-17 0001124105 2020-07-16 2020-07-17 xbrli:pure 0001124105 cbio:TwoThousandEighteenOmnibusIncentivePlanMember 2020-06-11 2020-06-11 0001124105 cbio:TwoThousandEighteenOmnibusIncentivePlanMember 2020-06-11 0001124105 2019-01-01 2019-12-31 0001124105 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001124105 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001124105 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001124105 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001124105 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001124105 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001124105 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001124105 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001124105 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001124105 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001124105 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001124105 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001124105 us-gaap:EmployeeStockOptionMember 2020-09-30 0001124105 us-gaap:CollaborativeArrangementMember cbio:PfizerIncMember srt:MaximumMember 2016-12-08 0001124105 us-gaap:CollaborativeArrangementMember cbio:PfizerIncMember 2018-02-01 2018-02-28 0001124105 us-gaap:CollaborativeArrangementMember cbio:PfizerIncMember 2020-01-01 2020-09-30 0001124105 cbio:AmendedAndRestatedLicenseAgreementMember cbio:IsuAbxisMember srt:MaximumMember 2020-01-01 2020-09-30 0001124105 cbio:AmendedAndRestatedLicenseAgreementMember cbio:IsuAbxisMember srt:MaximumMember 2018-12-01 2018-12-31 0001124105 cbio:AmendedAndRestatedLicenseAgreementMember cbio:IsuAbxisMember 2020-01-01 2020-09-30 0001124105 cbio:AmendedAndRestatedLicenseAgreementMember cbio:IsuAbxisMember 2018-12-01 2018-12-31 0001124105 cbio:LicenseAndCollaborationAgreementMember cbio:BiogenMember 2019-12-18 2019-12-18 0001124105 cbio:ExclusiveLicenseMember cbio:BiogenMember 2020-01-01 2020-01-31 0001124105 cbio:ExclusiveLicenseMember cbio:BiogenMember srt:MaximumMember 2020-01-01 2020-01-31 0001124105 cbio:LicenseRevenueMember cbio:TransferOfExclusiveLicenseAndRelatedKnowHowMember 2020-01-01 2020-09-30 0001124105 cbio:ExclusiveLicenseMember 2020-01-01 2020-09-30 0001124105 cbio:CollaborationRevenueMember cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember 2020-07-01 2020-09-30 0001124105 cbio:CollaborationRevenueMember cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember 2020-01-01 2020-09-30 0001124105 cbio:OptionsToPurchaseCommonStockMember 2020-01-01 2020-09-30 0001124105 cbio:OptionsToPurchaseCommonStockMember 2019-01-01 2019-09-30 0001124105 cbio:CommonStockWarrantsMember 2020-01-01 2020-09-30 0001124105 cbio:CommonStockWarrantsMember 2019-01-01 2019-09-30 0001124105 us-gaap:CommonStockMember 2020-02-28 2020-02-29 0001124105 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-02-28 2020-02-29 0001124105 us-gaap:CommonStockMember 2020-02-29 0001124105 2020-02-28 2020-02-29 0001124105 us-gaap:CommonStockMember 2020-06-29 2020-06-30 0001124105 2020-06-29 2020-06-30 0001124105 cbio:AGCBiologicsIncMember cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember 2020-09-30 0001124105 cbio:CatalentIndianaLLCMember cbio:DalcinonacogAlfaMember 2020-09-30 0001124105 cbio:MosaicBiosciencesIncMember us-gaap:CollaborativeArrangementMember cbio:IntravitrealAntiComplementFactor3Member 2020-01-01 2020-09-30 0001124105 cbio:MosaicBiosciencesIncMember us-gaap:CollaborativeArrangementMember cbio:IntravitrealAntiComplementFactor3Member 2019-01-01 2019-09-30 0001124105 cbio:MosaicBiosciencesIncMember us-gaap:CollaborativeArrangementMember cbio:IntravitrealAntiComplementFactor3Member 2020-07-01 2020-09-30 0001124105 cbio:MosaicBiosciencesIncMember us-gaap:CollaborativeArrangementMember cbio:IntravitrealAntiComplementFactor3Member 2019-07-01 2019-09-30 0001124105 cbio:BiogenMember cbio:LicenseAndCollaborationAgreementMember 2020-01-10 0001124105 cbio:MosaicBiosciencesIncMember 2020-01-01 2020-09-30 0001124105 cbio:MosaicBiosciencesIncMember 2020-05-08 2020-05-08 0001124105 cbio:MosaicBiosciencesIncMember srt:MaximumMember 2020-01-01 2020-09-30 0001124105 cbio:MosaicBiosciencesIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 000-51173

 

Catalyst Biosciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

56-2020050

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

 

611 Gateway Blvd., Suite 710

South San Francisco, California

94080

(Address of Principal Executive Offices)

(Zip Code)

(650) 871-0761

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

CBIO

 

NASDAQ

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of October 29, 2020, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 22,097,820.

 

 

 

 


CATALYST BIOSCIENCES, INC.

TABLE OF CONTENTS

 

 

 

 

 

Page No.

 

 

 

 

 

PART I. FINANCIAL INFORMATION

 

3

 

 

 

 

 

Item 1.

 

Financial Statements:

 

3

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019

 

3

 

 

 

 

 

 

 

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)

 

4

 

 

 

 

 

 

 

Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019 (unaudited)

 

5

 

 

 

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2020 and 2019 (unaudited)

 

6

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)

 

7

 

 

 

 

 

 

 

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

8

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

16

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

26

 

 

 

 

 

Item 4.

 

Controls and Procedures

 

27

 

 

 

 

 

PART II. OTHER INFORMATION

 

28

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

28

 

 

 

 

 

Item 1A.

 

Risk Factors

 

28

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

29

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities

 

29

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures

 

29

 

 

 

 

 

Item 5.

 

Other Information

 

29

 

 

 

 

 

Item 6.

 

Exhibits

 

29

 

 

 

 

 

Exhibit Index

 

30

 

 

 

 

 

Signatures

 

31

 

 

 

 


 

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

Catalyst Biosciences, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

 

 

 

September 30, 2020

 

 

December 31, 2019

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

24,923

 

 

$

15,369

 

Short-term investments

 

 

77,959

 

 

 

61,496

 

Accounts receivable

 

 

1,555

 

 

 

15,000

 

Prepaid and other current assets

 

 

3,535

 

 

 

4,201

 

Total current assets

 

 

107,972

 

 

 

96,066

 

Long-term investments

 

 

1,171

 

 

 

 

Other assets, noncurrent

 

 

698

 

 

 

257

 

Right-of-use assets

 

 

1,524

 

 

 

1,927

 

Property and equipment, net

 

 

439

 

 

 

304

 

Total assets

 

$

111,804

 

 

$

98,554

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

4,244

 

 

$

4,279

 

Accrued compensation

 

 

2,543

 

 

 

2,106

 

Deferred revenue

 

 

764

 

 

 

15,000

 

Other accrued liabilities

 

 

8,750

 

 

 

7,031

 

Operating lease liability

 

 

519

 

 

 

483

 

Total current liabilities

 

 

16,820

 

 

 

28,899

 

Operating lease liability, noncurrent

 

 

925

 

 

 

1,319

 

Total liabilities

 

 

17,745

 

 

 

30,218

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued

   and outstanding

 

 

 

 

 

 

Common stock, $0.001 par value, 100,000,000 shares authorized; 22,082,924 and

   12,040,835 shares issued and outstanding at September 30, 2020 and

   December 31, 2019, respectively

 

 

22

 

 

 

12

 

Additional paid-in capital

 

 

389,883

 

 

 

326,810

 

Accumulated other comprehensive income

 

 

8

 

 

 

34

 

Accumulated deficit

 

 

(295,854

)

 

 

(258,520

)

Total stockholders’ equity

 

 

94,059

 

 

 

68,336

 

Total liabilities and stockholders’ equity

 

$

111,804

 

 

$

98,554

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

3


 

Catalyst Biosciences, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

License

 

$

32

 

 

$

 

 

$

15,100

 

 

$

 

Collaboration

 

 

861

 

 

 

 

 

 

3,817

 

 

 

 

License and collaboration revenue

 

 

893

 

 

 

 

 

 

18,917

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of license

 

 

32

 

 

 

 

 

 

3,102

 

 

 

 

Cost of collaboration

 

 

879

 

 

 

 

 

 

4,030

 

 

 

 

Research and development

 

 

12,249

 

 

 

9,927

 

 

 

38,419

 

 

 

33,066

 

General and administrative

 

 

3,833

 

 

 

3,268

 

 

 

11,895

 

 

 

10,224

 

Total operating expenses

 

 

16,993

 

 

 

13,195

 

 

 

57,446

 

 

 

43,290

 

Loss from operations

 

 

(16,100

)

 

 

(13,195

)

 

 

(38,529

)

 

 

(43,290

)

Interest and other income, net

 

 

67

 

 

 

489

 

 

 

1,195

 

 

 

1,722

 

Net loss

 

$

(16,033

)

 

$

(12,706

)

 

$

(37,334

)

 

$

(41,568

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(0.73

)

 

$

(1.06

)

 

$

(2.05

)

 

$

(3.47

)

Shares used to compute net loss per share attributable to

   common stockholders, basic and diluted

 

 

22,072,243

 

 

 

12,022,620

 

 

 

18,199,575

 

 

 

11,992,240

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

4


 

Catalyst Biosciences, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net loss

 

$

(16,033

)

 

$

(12,706

)

 

$

(37,334

)

 

$

(41,568

)

Other comprehensive (loss) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale debt securities

 

 

(33

)

 

 

(26

)

 

 

(26

)

 

 

35

 

Total comprehensive loss

 

$

(16,066

)

 

$

(12,732

)

 

$

(37,360

)

 

$

(41,533

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

5


 

Catalyst Biosciences, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

 

Convertible

Preferred Stock

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2019

 

 

 

 

$

 

 

 

12,040,835

 

 

$

12

 

 

$

326,810

 

 

$

34

 

 

$

(258,520

)

 

$

68,336

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

7,817

 

 

 

 

 

 

805

 

 

 

 

 

 

 

 

 

805

 

Issuance of common stock from stock

   grants and option exercises

 

 

 

 

 

 

 

 

62,969

 

 

 

 

 

 

339

 

 

 

 

 

 

 

 

 

339

 

Issuance of common stock for public offering, net

   of issuance costs of $2,514

 

 

 

 

 

 

 

 

5,307,692

 

 

 

5

 

 

 

31,981

 

 

 

 

 

 

 

 

 

31,986

 

Unrealized gain on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

106

 

 

 

 

 

 

 

106

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,053

)

 

 

(4,053

)

Balance at March 31, 2020

 

 

 

 

 

 

 

 

17,419,313

 

 

 

17

 

 

 

359,935

 

 

 

140

 

 

 

(262,573

)

 

 

97,519

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

16,048

 

 

 

 

 

 

834

 

 

 

 

 

 

 

 

 

834

 

Issuance of common stock for public offering, net

   of issuance costs of $2,045

 

 

 

 

 

 

 

 

4,615,384

 

 

 

5

 

 

 

27,950

 

 

 

 

 

 

 

 

 

27,955

 

Unrealized loss on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(99

)

 

 

 

 

 

(99

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(17,248

)

 

 

(17,248

)

Balance at June 30, 2020

 

 

 

 

 

 

 

 

22,050,745

 

 

 

22

 

 

 

388,719

 

 

 

41

 

 

 

(279,821

)

 

 

108,961

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

12,295

 

 

 

 

 

 

1,068

 

 

 

 

 

 

 

 

 

1,068

 

Issuance of common stock from stock grants

 

 

 

 

 

 

 

 

19,884

 

 

 

 

 

 

96

 

 

 

 

 

 

 

 

 

96

 

Unrealized loss on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(33

)

 

 

 

 

 

(33

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16,033

)

 

 

(16,033

)

Balance at September 30, 2020

 

 

 

 

$

 

 

 

22,082,924

 

 

$

22

 

 

$

389,883

 

 

$

8

 

 

$

(295,854

)

 

$

94,059

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible

Preferred Stock

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

Other

Comprehensive

 

 

Accumulated

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2018

 

 

 

 

$

 

 

 

11,954,528

 

 

$

12

 

 

$

323,279

 

 

$

(4

)

 

$

(203,342

)

 

$

119,945

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

829

 

 

 

 

 

 

 

 

 

829

 

Issuance of common stock from stock

   grants and option exercises

 

 

 

 

 

 

 

 

19,576

 

 

 

 

 

 

106

 

 

 

 

 

 

 

 

 

106

 

Unrealized gain on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17

 

 

 

 

 

 

17

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(15,082

)

 

 

(15,082

)

Balance at March 31, 2019

 

 

 

 

 

 

 

 

11,974,104

 

 

 

12

 

 

 

324,214

 

 

 

13

 

 

 

(218,424

)

 

 

105,815

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

5,999

 

 

 

 

 

 

903

 

 

 

 

 

 

 

 

 

903

 

Issuance of common stock from option exercises

 

 

 

 

 

 

 

 

28,425

 

 

 

 

 

 

129

 

 

 

 

 

 

 

 

 

129

 

Unrealized gain on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

44

 

 

 

 

 

 

44

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,780

)

 

 

(13,780

)

Balance at June 30, 2019

 

 

 

 

 

 

 

 

12,008,528

 

 

 

12

 

 

 

325,246

 

 

 

57

 

 

 

(232,204

)

 

 

93,111

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

7,393

 

 

 

 

 

 

801

 

 

 

 

 

 

 

 

 

801

 

Issuance of common stock from stock grants and option exercises

 

 

 

 

 

 

 

 

14,071

 

 

 

 

 

 

92

 

 

 

 

 

 

 

 

 

92

 

Unrealized loss on available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(26

)

 

 

 

 

 

(26

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(12,706

)

 

 

(12,706

)

Balance at September 30, 2019

 

 

 

 

$

 

 

 

12,029,992

 

 

$

12

 

 

$

326,139

 

 

$

31

 

 

$

(244,910

)

 

$

81,272

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6


 

Catalyst Biosciences, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2020

 

 

2019

 

Operating Activities

 

 

 

 

 

 

 

 

Net loss

 

$

(37,334

)

 

$

(41,568

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

2,707

 

 

 

2,533

 

Depreciation and amortization

 

 

93

 

 

 

112

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

13,445

 

 

 

 

Prepaid and other assets

 

 

225